Multiple adipose depots increase cardiovascular risk via local and systemic effects topical collection on clinical trials and their interpretations

Current Atherosclerosis Reports

Volumn 15, Issue 10, 2013, Pages

  Karastergiou, Kalypso ^a   Fried, Susan K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epicardial adipose tissue; Gluteofemoral adipose tissue; Renal sinus adipose tissue; Subcutaneous adipose tissue; Visceral adipose tissue

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DIET; DISEASE COURSE; DISEASE SEVERITY; EPICARDIUM; EXERCISE; HEART MUSCLE; HUMAN; INTRAABDOMINAL FAT; LIPID STORAGE; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; RENAL ARTERY; RISK FACTOR; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MODEL; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HUMANS; OBESITY; RISK FACTORS;

EID: 84897366439     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0361-5     Document Type: Article

References (105)

1. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-9.
2. Samocha-Bonet D, Chisholm DJ, Tonks K, Campbell LV, Greenfield JR. Insulin-sensitive obesity in humans - a 'favorable fat' phenotype? Trends Endocrinol Metab. 2012;23:116-24.
3. Cinti S. The adipose organ: morphological perspectives of adipose tissues. Proc Nutr Soc. 2001;60:319-28.
4. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013;34:1-11.
5. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20-34.
6. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404.
7. Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085-95.
8. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. 2011;12:680-7.
9. Bouchard C. BMI, fat mass, abdominal adiposity and visceral fat: where is the 'beef'? Int J Obes (Lond). 2007;31:1552-3. (Pubitemid 47482662)
10. Chrysant SG, Chrysant GS. New insights into the true nature of the obesity paradox and the lower cardiovascular risk. J Am Soc Hypertens. 2013;7:85-94.
11. • Coutinho T, Goel K, Corrêa de Sá D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011;57:1877-86. This study shows that there is no "central obesity paradox," i.e., central fat distribution is associated with increased morbidity/mortality in subjects with established cardiovascular disease.
12. Coutinho T, Goel K, Corrêa de Sá D, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of normal weight central obesity. J Am Coll Cardiol. 2013;61:553-60.
13. • Cameron AJ, Magliano DJ, Söderberg S. A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. Obes Rev. 2013;14:86-94. This is a recent meta-analysis illustrating the independent relationship between peripheral fat distribution and morbidity/mortality.
14. Heitmann BL, Lissner L. Hip hip hurrah! Hip size inversely related to heart disease and total mortality. Obes Rev. 2011;12:478-81.
15. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond). 2010;34:949-59.
16. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34:210-5.
17. Appleton SL, Seaborn CJ, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013;36:2388-94.
18. Vega GL, Adams-Huet B, Peshock R, et al. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab. 2006;91:4459-66. (Pubitemid 44833423)
19. Ogorodnikova AD, Kim M, McGinn AP, et al. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring). 2012;20:651-9.
20. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97:2482-8.
21. Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34:389-97.
22. Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230-6.
23. •• Cornier MA, Després JP, Davis N, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996-2019. This is a recent review of the epidemiology of obesity and its related comorbidities, together with issues and methods available for assessing adiposity in adults. It concludes with practical recommendations for the clinician in practice towards identifying more at-risk overweight/obese individuals.
24. Katzmarzyk PT, Bray GA, Greenway FL, et al. Ethnic-specific BMI and waist circumference thresholds. Obesity (Silver Spring). 2011;19:1272-8.
25. Katzmarzyk PT, Heymsfield SB, Bouchard C. Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults. Am J Clin Nutr. 2013;97:480-6.
26. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920-2.
27. Knowles KM, Paiva LL, Sanchez SE, et al. Waist circumference, body mass index, and other measures of adiposity in predicting cardiovascular disease risk factors among Peruvian adults. Int J Hypertens. 2011;2011:931402.
28. Mohammadreza B, Farzad H, Davoud K, Fereidoun PA. Prognostic significance of the complex visceral adiposity index vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol. 2012;11:20.
29. Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Invest. 2013;43:183-9.
30. Zhang X, Shu XO, Li H, et al. Visceral adiposity and risk of coronary heart disease in relatively lean Chinese adults. Int J Cardiol. 2013. doi: 10.1016/j.ijcard.2013.01.275.
31. Arsenault BJ, Lemieux I, Després JP, et al. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ. 2010;182:1427-32.
32. de Graaf FR, Schuijf JD, Scholte AJ, et al. Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol. 2010;106:1747-53.
33. Blackburn P, Lemieux I, Lamarche B, et al. Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. Metabolism. 2012;61:56-64.
34. Bergman RN, Stefanovski D, Buchanan TA, et al. A better index of body adiposity. Obesity (Silver Spring). 2011;19:1083-9.
35. Melmer A, Lamina C, Tschoner A, et al. Body adiposity index and other indexes of body composition in the SAPHIR study: association with cardiovascular risk factors. Obesity (Silver Spring). 2013;21:775-81. doi: 10.1002/oby.20289.
36. Moliner-Urdiales D, Artero EG, Lee DC, et al. Body adiposity index and all-cause and cardiovascular disease mortality in men. Obesity (Silver Spring). 2013. doi: 10.1002/oby.20399.
37. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13:275-86.
38. Sluik D, Boeing H, Montonen J, et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011;174:22-34.
39. Trefethen LN. New BMI (new body mass index). http://people.maths.ox.ac. uk/trefethen/bmi.html (2013). Accessed 4 Apr 2013.
40. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48. (Pubitemid 47016245)
41. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham Heart Study. Obesity (Silver Spring). 2010;18:2191-8.
42. Smith JD, Borel AL, Nazare JA, et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab. 2012;97:1517-25.
43. Kaess BM, Pedley A, Massaro JM, et al. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55:2622-30.
44. Nazare JA, Smith JD, Borel AL, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. Am J Clin Nutr. 2012;96:714-26.
45. Lear SA, Chockalingam A, Kohli S, Richardson CG, Humphries KH. Elevation in cardiovascular disease risk in South Asians is mediated by differences in visceral adipose tissue. Obesity (Silver Spring). 2012;20:1293-300.
46. Ding J, Hsu FC, Harris TB, et al. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2009;90:499-504.
47. Huang G, Wang D, Zeb I, et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis. 2012;221:198-205.
48. Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30:850-6.
49. Thanassoulis G, Massaro JM, Hoffmann U, et al. Prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat depots in the Framingham Heart Study. Circ Cardiovasc Imaging. 2010;3:559-66.
50. Britton KA, Pedley A, Massaro JM, et al. Prevalence, distribution, and risk factor correlates of high thoracic periaortic fat in the Framingham Heart Study. J Am Heart Assoc. 2012;1:e004200.
51. Yerramasu A, Dey D, Venuraju S, et al. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis. 2012;220:223-30.
52. Nakanishi R, Rajani R, Cheng VY, et al. Increase in epicardial fat volume is associated with greater coronary artery calcification progression in subjects at intermediate risk by coronary calcium score: a serial study using non-contrast cardiac CT. Atherosclerosis. 2011;218:363-8.
53. Albuquerque FN, Somers VK, Blume G, et al. Usefulness of epicardial adipose tissue as predictor of cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2012;110:1100-5.
54. •• Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2013;61:1388-95. This prospective study shows that EAT volume is associated with fatal and nonfatal coronary events in the general population independently of traditional cardiovascular risk factors.
55. Chughtai HL, Morgan TM, Rocco M, et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56:901-6.
56. Foster MC, Hwang SJ, Porter SA, et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58:784-90.
57. Janiszewski PM, Saunders TJ, Ross R. Breast volume is an independent predictor of visceral and ectopic fat in premenopausal women. Obesity (Silver Spring). 2010;18:1183-7.
58. Schautz B, Later W, Heller M, Müller MJ, Bosy-Westphal A. Associations between breast adipose tissue, body fat distribution and cardiometabolic risk in women: cross-sectional data and weight-loss intervention. Eur J Clin Nutr. 2011;65:784-90.
59. Carobbio S, Rodriguez-Cuenca S, Vidal-Puig A. Origins of metabolic complications in obesity: ectopic fat accumulation. The importance of the qualitative aspect of lipotoxicity. Curr Opin Clin Nutr Metab Care. 2011;14:520-6.
60. Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313-25.
61. McLaughlin TM, Liu T, Yee G, et al. Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring). 2010;18:926-31.
62. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939-49. (Pubitemid 40712793)
63. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216:T17-36.
64. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia. 2011;54:2515-24.
65. Kizer JR, Benkeser D, Arnold AM, et al. Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation. 2012;126:2951-61.
66. Wilson SR, Sabatine MS, Wiviott SD, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin or Atorvastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011;161:1147-55.
67. Hascoet S, Elbaz M, Bongard V, et al. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol. 2013;33:e19-29.
68. + T cells. J Biol Chem. 2012;287:36896-904.
69. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32:S13-8.
70. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51:8-14. (Pubitemid 350307092)
71. Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflam. 2011;2011:376909.
72. Björntorp P. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493-6. (Pubitemid 20220571)
73. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest. 2004;113:1582-8. (Pubitemid 39071681)
74. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Br J Nutr. 2000;83 Suppl 1:S71-7.
75. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56:1010-3. (Pubitemid 46525079)
76. Karastergiou K, Evans I, Ogston N, et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30:1340-6.
77. Greulich S, Maxhera B, Vandenplas G, et al. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation. 2012;126:2324-34.
78. Venteclef N, Guglielmi V, Balse E, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J. 2013. doi: 10.1093/eurheartj/eht099.
79. Lee YC, Chang HH, Chiang CL, et al. Role of perivascular adipose tissue-derived methyl palmitate in vascular tone regulation and pathogenesis of hypertension. Circulation. 2011;124:1160-71.
80. Goossens GH, Bizzarri A, Venteclef N, et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation. 2011;124:67-76.
81. Gealekman O, Guseva N, Hartigan C, et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation. 2011;123:186-94.
82. • Chang L, Villacorta L, Li R, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012;126:1067-78. This study shows that murine perivascular adipose tissue has features of brown fat and that loss of this depot results in impaired vascular thermoregulation and promotes atherosclerosis.
83. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430-5.
84. •• Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010;139:448-55. In this randomized controlled trial, a decrease in VAT mass through omentectomy, alone or in combination with Roux-en-Y gastric bypass surgery, did not improve insulin sensitivity in obese patients.
85. Herrera MF, Pantoja JP, Velázquez-Fernández D, et al. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial. Diabetes Care. 2010;33:1413-8.
86. Dillard TH, Purnell JQ, Smith MD, et al. Omentectomy added to Roux-en-Y gastric bypass surgery: a randomized, controlled trial. Surg Obes Relat Dis. 2011;9:269-75.
87. Tamboli RA, Hajri T, Jiang A, et al. Reduction in inflammatory gene expression in skeletal muscle from Roux-en-Y gastric bypass patients randomized to omentectomy. PLoS One. 2011;6:e28577.
88. Wu J, Ye H, Wang Y, et al. Comparative study of laparoscopic sleeve gastrectomy with and without partial enterectomy and omentectomy. Surg Obes Relat Dis. 2012;8:275-80.
89. Dunn JP, Abumrad NN, Breitman I, et al. Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care. 2012;35:137-42.
90. Lima MM, Pareja JC, Alegre SM, et al. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines and inflammatory markers. Obesity (Silver Spring). 2013;21:E182-9. doi: 10.1002/oby.20030.
91. Sdralis E, Argentou M, Mead N, et al. A prospective randomized study comparing patients with morbid obesity submitted to sleeve gastrectomy with or without omentectomy. Obes Surg. 2013;23:965-71.
92. Romaguera D, Norat T, Mouw T, et al. Adherence to the Mediterranean diet is associated with lower abdominal adiposity in European men and women. J Nutr. 2009;139:1728-37.
93. Romaguera D, Ängquist L, Du H, et al. Food composition of the diet in relation to changes in waist circumference adjusted for body mass index. PLoS One. 2011;6:e23384.
94. • Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-90. This is a randomized controlled trial with 7,447 participants at high risk of cardiovascular disease assigned to two Mediterranean diets or a control diet. The study was terminated prematurely owing to the protective effect of the Mediterranean diet on major cardiovascular events.
95. de Souza RJ, Bray GA, Carey VJ, et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr. 2012;95:614-25.
96. Ismail I, Keating SE, Baker MK, Johnson NA. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat. Obes Rev. 2012;13:68-91.
97. Vissers D, Hens W, Taeymans J, et al. The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One. 2013;8:e56415.
98. Murphy JC, McDaniel JL, Mora K, et al. Preferential reductions in intermuscular and visceral adipose tissue with exercise-induced weight loss compared with calorie restriction. J Appl Physiol. 2012;112:79-85.
99. Hunter GR, Brock DW, Byrne NM, et al. Exercise training prevents regain of visceral fat for 1 year following weight loss. Obesity (Silver Spring). 2010;18:690-5.
100. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab. 2007;293(2):E444-52. (Pubitemid 47205086)
101. Cypess AM, White AP, Vernochet C, Schulz TJ, Xue R, Sass CA, et al. Anatomical localization, gene expression profiling and functional characterization of adult human neck brown fat. Nat Med. 2013;19(5):635-9.
102. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150(2):366-76. doi: 10.1016/j.cell.2012.05.016.
103. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E, Carpentier AC, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab. 2011;96(1):192-9.
104. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012;97:E1229-33.
105. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013;27(3):234-50.